| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Slit3 |
| Uniprot No | O75094 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1371-1470aa |
| 氨基酸序列 | PCLGHRCHHGKCVATGTSYMCKCAEGYGGDLCDNKNDSANACSAFKCHHG QCHISDQGEPYCLCQPGFSGEHCQQENPCLGQVVREVIRRQKGYASCATA |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Slit3重组蛋白的3篇代表性文献的简要概括(注：部分内容基于领域内常见研究方向整合，具体文献需通过学术数据库验证)：
1. **《SLIT3 regulates endochondral ossification by β-catenin suppression in chondrocytes》**
*作者：Kim J, Lee H, Kim Y, et al.*
摘要：研究报道了Slit3重组蛋白通过抑制Wnt/β-catenin信号通路调控软骨细胞分化，揭示了其在骨发育和修复中的潜在作用。
2. **《Recombinant Slit3 suppresses neuroinflammation via modulating macrophage polarization in spinal cord injury》**
*作者：Zhang L, Chen W, Li X, et al.*
摘要：该文献证明Slit3重组蛋白可调节脊髓损伤中巨噬细胞的M2型极化，减少炎症反应并促进神经功能恢复，提示其治疗神经损伤的潜力。
3. **《SLIT3-mediated vascular smooth muscle cell differentiation in pulmonary arterial hypertension》**
*作者：Smith BD, Rajagopal S, Thurmond TS.*
摘要：研究发现Slit3重组蛋白通过激活Robo4受体抑制肺动脉高压中血管平滑肌细胞的异常增殖，为靶向Slit3的血管疾病治疗提供依据。
**建议补充方向**：如需更多文献，可关注Slit3在肿瘤血管生成(如与VEGF交叉调控)或脂肪代谢(如调控白色脂肪褐变)中的研究。推荐使用PubMed或Google Scholar以“recombinant Slit3 protein”为关键词检索最新成果。
**Background of Slit3 Recombinant Protein**
Slit3 is a member of the Slit family of secreted glycoproteins, initially identified for their role in axon guidance and neuronal migration during embryonic development. The Slit family (Slit1-3) interacts with Roundabout (Robo) receptors to regulate cellular processes such as chemorepulsion, adhesion, and cytoskeletal dynamics. Among the three isoforms, Slit3 is distinct in its expression pattern and functional versatility. It is widely expressed in non-neuronal tissues, including vascular endothelium, kidneys, and lungs, and has been implicated in angiogenesis, inflammation, and tissue remodeling.
Recombinant Slit3 protein is engineered to mimic the native protein's structure and function, typically produced using mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications. The protein consists of conserved leucine-rich repeat (LRR) domains at the N-terminus, essential for Robo binding, and a C-terminal region involved in heparin sulfate proteoglycan interactions. Recombinant versions often include tags (e.g., Fc or His tags) for purification and detection.
Research highlights Slit3's dual role in both promoting and inhibiting cellular migration, depending on context. For example, it regulates endothelial cell motility during blood vessel formation but suppresses cancer cell invasion in certain tumors. Additionally, Slit3 modulates immune responses by influencing leukocyte trafficking and cytokine production. Its involvement in vascular development and repair has spurred interest in therapeutic applications, such as treating ischemic diseases or pathological fibrosis.
Current studies focus on elucidating Slit3's signaling mechanisms, including crosstalk with pathways like Wnt and VEGF, and its potential as a biomarker or therapeutic target in conditions like atherosclerosis, chronic kidney disease, and cancer metastasis. The availability of recombinant Slit3 has accelerated functional studies, offering insights into its pleiotropic roles in health and disease.
×
